KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) Meeting Abstract
| Authors: | Rugo, H.; Llombart-Cussac, A.; Andre, F.; Robson, M. E.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D.; Ahn, J. S.; Nanda, R.; Fan, L.; Mejia, J. A.; Karantza, V.; Bardia, A. |
| Abstract Title: | KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700101 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-OT-30-01 |
| Notes: | Meeting Abstract: OT-30-01 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
